BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fabrizi F, Martin P, Messa P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89:988-994. [PMID: 27083277 DOI: 10.1016/j.kint.2016.01.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Piano S, Romano A, Di Pascoli M, Angeli P. Why and how to measure renal function in patients with liver disease. Liver Int. 2017;37 Suppl 1:116-122. [PMID: 28052631 DOI: 10.1111/liv.13305] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
2 Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, Renjifo B, Wang D, Shuster DL, Cohen DE, Jacobson IM. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Kidney Int Rep 2019;4:245-56. [PMID: 30775621 DOI: 10.1016/j.ekir.2018.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 El-Sayed M, Abdellatif Z, Elsharkawy A, El Kassas M, Abd Elmoniem R, Marzouk A, Fouad R, Esmat G, Abdel Alem S. Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. Infection 2020;48:913-22. [PMID: 32816249 DOI: 10.1007/s15010-020-01505-5] [Reference Citation Analysis]
4 Kozlovskaya LV, Rameev VV, Kogarko IN, Gordovskaya NB, Chebotareva NV, Androsova TV, Roshchupkina SV, Mrykhin NN, Russkikh AV, Loshkareva OA, Sidorova EI. Renal lesions associated with monoclonal gammopathies of undetermined significance: clinical forms, mechanisms of development, approaches to treatment. Klin med 2017;94:892-901. [DOI: 10.18821/0023-2149-2016-94-12-892-901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Papadopoulos N, Griveas I, Sveroni E, Argiana V, Kalliaropoulos A, Martinez-Gonzalez B, Deutsch M. HCV viraemia in anti-HCV-negative haemodialysis patients: Do we need HCV RNA detection test? Int J Artif Organs 2018;41:168-70. [PMID: 29546809 DOI: 10.1177/0391398817752326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. J Gen Intern Med. 2018;33:551-557. [PMID: 29352420 DOI: 10.1007/s11606-017-4280-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
7 Alkadi MM, Abuhelaiqa EA, Elshirbeny MF, Hamdi AF, Fituri OM, Asim M, Alkaabi SR, Derbala MF, Jarman ME, Ashour AM, Nauman A, Al Maslamani YK, Butt AA, Al-Malki HA. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience. Immun Inflamm Dis 2021;9:246-54. [PMID: 33264509 DOI: 10.1002/iid3.386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Lu T, Bian Y, Zhu Y, Guo M, Yang Y, Guo J, Gu C, Duan JA. HUANGKUISIWUFANG inhibits pyruvate dehydrogenase to improve glomerular injury in anti-Thy1 nephritis model. J Ethnopharmacol 2020;253:112682. [PMID: 32087318 DOI: 10.1016/j.jep.2020.112682] [Reference Citation Analysis]
9 Gentil MA, González-Corvillo C, Perelló M, Zarraga S, Jiménez-Martín C, Lauzurica LR, Alonso A, Franco A, Hernández-Marrero D, Sánchez-Fructuoso A. Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study. Transplant Proc 2016;48:2944-6. [PMID: 27932113 DOI: 10.1016/j.transproceed.2016.07.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
10 Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018; 8(4): 84-96 [PMID: 30148074 DOI: 10.5500/wjt.v8.i4.84] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
11 Elmowafy AY, El Maghrabi HM, Mashaly ME, Eldahshan KF, Rostaing L, Bakr MA. High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents. Int Urol Nephrol 2019;51:2243-54. [PMID: 31612423 DOI: 10.1007/s11255-019-02316-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Alkhouri N, Lawitz E, Poordad F. Novel treatments for chronic hepatitis C: closing the remaining gaps. Curr Opin Pharmacol 2017;37:107-11. [PMID: 29121533 DOI: 10.1016/j.coph.2017.10.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
13 Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017;2:52-62. [PMID: 28404015 DOI: 10.1016/s2468-1253(16)30080-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
14 Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, Hsu CS, Hui YT, Li MKK, Liu CH, Kan YM, Yu ML, Yuen MF. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. Clin Mol Hepatol 2020;26:554-61. [PMID: 32854457 DOI: 10.3350/cmh.2020.0058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Muñoz-Gómez R, Rincón D, Ahumada A, Hernández E, Devesa MJ, Izquierdo S, Ortiz M, Hernández-Albujar A, Fernández-Rodríguez C, Calvo M, González R, Lozano M, Castellano G, Fernández-Vázquez I. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. J Viral Hepat 2017;24:464-71. [PMID: 27976490 DOI: 10.1111/jvh.12664] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
16 Morishita A, Ogawa C, Moriya A, Tani J, Yoneyama H, Fujita K, Oryu M, Senoo T, Takaguchi K, Masaki T. Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study. Hepatol Res 2020;50:557-64. [PMID: 31883211 DOI: 10.1111/hepr.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dejman A, Ladino MA, Roth D. Treatment and management options for the hepatitis C virus infected kidney transplant candidate. Hemodial Int 2018;22 Suppl 1:S36-44. [PMID: 29694726 DOI: 10.1111/hdi.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
18 Chen YC, Li CY, Tsai SJ, Chen YC. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World J Clin Cases 2019; 7(11): 1270-1281 [PMID: 31236391 DOI: 10.12998/wjcc.v7.i11.1270] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Medeiros T, Rosário NF, Saraiva GN, Andrade TG, Silva AA, Almeida JR. Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian "real-life" study. J Clin Pharm Ther 2018;43:707-13. [PMID: 29737025 DOI: 10.1111/jcpt.12697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
20 Jie Y, Lin C, Yuan J, Zhao Z, Guan Y, Zhou Y, Zhou X, Zhong B, Ye Y, Zhang L, Tao L, Li J, Zhang X, Chong Y. Real-world effectiveness and safety of OBT/PTV/r and dasabuvir for patients with chronic HCV genotype 1b infection in China: A multicenter prospective observational study. Liver Research 2020;4:153-8. [DOI: 10.1016/j.livres.2020.06.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Ivanenkov YA, Aladinskiy VA, Bushkov NA, Ayginin AA, Majouga AG, Ivachtchenko AV. Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). Expert Opin Ther Pat 2017;27:401-14. [PMID: 27967269 DOI: 10.1080/13543776.2017.1272573] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
22 Gallegos-Orozco JF, Kim R, Thiesset HF, Hatch J, Lynch K, Chaly T Jr, Shihab F, Ahmed F, Hall I, Campsen J. Early Results of Pilot Study Using Hepatitis C Virus (HCV) Positive Kidneys to Transplant HCV Infected Patients with End-Stage Renal Disease Allowing for Successful Interferon-Free Direct Acting Antiviral Therapy after Transplantation. Cureus 2016;8:e890. [PMID: 28018760 DOI: 10.7759/cureus.890] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Alric L, Ollivier-Hourmand I, Bérard E, Hillaire S, Guillaume M, Vallet-Pichard A, Bernard-Chabert B, Loustaud-Ratti V, Bourlière M, de Ledinghen V, Fouchard-Hubert I, Canva V, Minello A, Nguyen-Khac E, Leroy V, Saadoun D, Trias D, Pol S, Kamar N. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney Int 2018;94:206-13. [PMID: 29735308 DOI: 10.1016/j.kint.2018.02.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
24 Llenas-García J, Padilla S, Masiá M, Gutiérrez F. Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection. Enferm Infecc Microbiol Clin (Engl Ed) 2018;36:457. [PMID: 29217095 DOI: 10.1016/j.eimc.2017.10.012] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Maduell F, Belmar L, Ugalde J, Laguno M, Martínez-Rebollar M, Ojeda R, Arias M, Rodas L, Rossi F, Llovet LP, González LN, Mallolas J, Londoño MC. Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. Gastroenterol Hepatol 2019;42:164-70. [PMID: 30293914 DOI: 10.1016/j.gastrohep.2018.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Skladany L, Janceková D, Svac J. Hepatitis C virus antibodies in outpatients with chronic kidney disease. Clin Exp Hepatol 2018;4:267-70. [PMID: 30603675 DOI: 10.5114/ceh.2018.80129] [Reference Citation Analysis]
27 Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories. J Viral Hepat 2017;24:442-53. [DOI: 10.1111/jvh.12681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]